Drugs / flubendazole
flubendazole
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06128447 Comparator | Feb 2025 → May 2026 overdue | intestinal helminthiasis | Zero Point Five Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | flubendazole | “oral, chewable tablet formulation of flubendazole” NCT06128447 ↗ |
| Known as | Flubendazol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1454946 ↗ |
| Known as | NSC-313680 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1454946 ↗ |
| Known as | R 17,889 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1454946 ↗ |
| Modality | Small molecule | — CHEMBL1454946 ↗ |
| Route | Oral | “oral, chewable tablet formulation of flubendazole” NCT06128447 ↗ |